AstraZeneca PLC

Phase 3 AI-extracted

Truqap

PTEN-deficient metastatic hormone-sensitive prostate cancer

Resolved

340days ago

Phase 3 readout · Aug 1, 2025

What's at stake Phase 3 trial results for Truqap in PTEN-deficient metastatic hormone-sensitive prostate cancer are due Aug 1, 2025. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 14h ago

“Results from the primary analysis of the CAPItello-281 Phase III trial showed a statistically significant 19% reduction in the risk of radiographic disease progression or death and a clinically meaningful improvement in median radiographic ”

Add to calendar Post on X Reddit

Provenance